Core Insights - Waldencast plc (NASDAQ:WALD) is a skincare company known for advanced treatments, established in 1988, with a portfolio including brands like Obagi Medical and Obagi Clinical [1] Financial Performance - The stock target price for Waldencast has been adjusted from $4.13 to $3.25, with D.A. Davidson setting a higher target of $15.50, indicating differing analyst expectations [2][6] - Waldencast reported a net revenue of $65.4 million for Q1 2025, a decline of 4.1% year-over-year, with an adjusted gross margin of 76.4% and adjusted EBITDA of $4.4 million [3][6] - The company is experiencing margin pressure and negative earnings due to high SG&A expenses and significant debt, yet maintains manageable liquidity and a long debt maturity timeline extending to 2030 [5][6] Earnings Call - The Q1 2025 earnings call featured key figures such as CEO Michel Brousset and CFO Manuel Manfredi, with participation from analysts at firms like Alliance Global Partners and TD Cowen [4]